Accurate detection and localization of early-stage breast cancer represent the cornerstone for improving cancer cure rates and extending patient survival. However, selecting therapeutic regimens characterized by high efficacy and minimal side effects remains a formidable clinical challenge. Combining these two goals is now feasible with the innovation and progress of nanomaterials. Herein, we designed and synthesized a novel nanomaterial PDA@Fe-BTC@ MnO 2 nanoparticles (PFMPP NPs) for breast cancer. The MnO 2 and Fe-BTC units confer tumor-microenvironment (TME)-responsive T 1 /T 2 dual-mode magnetic resonance imaging (MRI)capability. For therapy, the Fe-BTC structure mediates chemodynamic therapy (CDT) via the Fenton-like reaction, generating cytotoxic reactive oxygen species (ROS). Simultaneously, the MnO 2 component catalyzes H 2 O 2 decomposition to relieve tumor hypoxia and consumes reduced glutathione (GSH) to protect ROS from clearance. Furthermore, PFMPP NPs exhibit strong photothermal conversion under 808 nm near-infrared light, permitting direct tumor ablation via photothermal therapy (PTT). The localized heating also enhances the Fenton-like reaction, yielding more ROS and thereby enabling enhanced combined therapeutic efficacy. This integrated strategy provides a feasible approach for theranostic applications in breast cancer.
Liu et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: